Phase I/II dose-expansion trial of epcoritamab, a novel, subcutaneous CD3- and CD20-targeting bispecific T-cell-engaging antibody, for the treatment of relapsed or refractory large B-cell lymphoma
In this medfyle
Subcutaneous epcoritamab resulted in deep and durable responses in highly refractory patients with LBCL, including those with prior CAR T-cell exposure, in the phase I/II dose-escalation/dose-expansion study EPCORE NHL-1.
About this Medfyle
©2023 Medfyle. All rights reserved.
Original article: Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. PMID: 36548927; PMCID: PMC10115554.
The authors of the original article and the publisher were not involved in the creation of the summary.
The authors of the original article, the publisher and ASCO were not involved in the creation of the summary.
